Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia
[at noodls] – HAIFA, Israel February 21, 2013 – Pluristem Therapeutics Inc. (NASDAQCM: PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and Drug Administration … more
View todays social media effects on PSTI
View the latest stocks trending across Twitter. Click to view dashboard